The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Open accessAbstract
BACKGROUND: A low plasma level of low-density lipoprotein (LDL) cholesterol is associated with reduced risk of coronary heart disease (CHD), but the effect of lifelong reductions in plasma LDL cholesterol is not known. We examined the effect of DNA-sequence variations that reduce plasma levels of LDL cholesterol on the incidence of coronary events in a large population. METHODS: We compared the incidence of CHD (myocardial infarction, fatal CHD, or coronary revascularization) over a 15-year interval in the Atherosclerosis Risk in Communities study according to the presence or absence of sequence variants in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) that are associated with reduced plasma levels of LDL cholesterol. RESULTS: Of the 3363 black subjects examined, 2.6 percent had nonsense mutations in PCSK9; these mutations were associated with a 28 percent reduction in mean LDL cholesterol and an 88 percent reduction in the risk of CHD (P=0.008 for the reduction; hazard ratio, 0.11; 95 percent confidence interval, 0.02 to 0.81; P=0.03). Of the 9524 white subjects examined, 3.2 percent had a sequence variation in PCSK9 that was associated with a 15 percent reduction in LDL cholesterol and a 47 percent reduction in the risk of CHD (hazard ratio, 0.50; 95 percent confidence interval, 0.32 to 0.79; P=0.003). CONCLUSIONS: These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Proprotein convertase subtilisin-kexin type 9 (PCSK9) promotes degradation of LDL receptors, thereby diminishing the clearance of LDL from the circulation. 6”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2005, a causative association was established between the presence of loss-of-function mutations in PCSK9 and lifelong reductions in LDL-C associated with lower CHD risk (3).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic studies have shown that carriage of PCSK9 loss-of-function alleles is associated with lower LDL cholesterol levels and a reduced risk of myocardial infarction.7,8”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that drugs that ultimately reduce LDL-C level predominantly through upregulation of LDL receptor expression should, barring any off-target adverse effects, lead to clinical benefit in proportion to the degree of LDL-C reduction.64”
From Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis (2016) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [44]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike gain-of-function PCSK9 variants (7), loss-of-function (LOF) variants enhance LDLR levels and promote LDLc clearance (4, 8).”
From Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Whereas PCSK9 loss-of-function mutations carriers with lifelong reductions in LDL-C and coronary heart disease incidence, were not initially found at significantly reduced risk of stroke (3, 72), a much larger study of the UK Biobank database described the first genetic evidence of a protective effect of the R46L loss-of-function mutation on PCSK9 on ischemic stroke (73).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [3]
In the citing paper
“and that lowering LDL-C reduces the risk of ASCVD proportionally to the absolute achieved reduction in LDL-C [2,51].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“The remarkable consistency among these studies, in addition to biological and experimental evidence, provides compelling evidence that LDL-C is causally associated with the risk of ASCVD”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“Both studies had relatively short follow-up periods and the evidence from statin trials indicates that the clinical benefits of LDL-lowering may only emerge after about 1 year [51], so these trials may have underestimated the potential impact of longer-term treatment [120,290].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“These developments have enabled researchers to bridge the gap between the monogenic and polygenic realms, identifying common variant modifiers of monogenic phenotypes contributing to the variable expression of rare, large-effect alleles26,93, and low-frequency and rare variants that influence common multifactorial traits94,95.”
From A brief history of human disease genetics (2020) · cites this paper as [95]
In the citing paper
“At the same time, it has become increasingly evident now that not only the magnitude of LDL-C lowering is important but that the duration of exposure to elevated LDL-C levels is equally important [11,16,38].”
In the citing paper
“Additionally, increasing evidence also suggests that the duration of exposure to low LDL-C levels may be as important as the magnitude of LDL-C lowering [11][12][13][14][15][16].”
In the citing paper
“The exceptionally low rates of CV events observed in patients carrying mutations in PCSK9 or other similar genes despite only modestly low LDL-C levels strongly support this notion [11].”
In the citing paper
“Hobbs and Cohen sequenced the gene (126, 127) and identified low-frequency common variants (0.5 to 1%), which allowed epidemiological research documenting a protective effect on myocardial infarction (128).”
From Genetic Mapping in Human Disease (2008) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
(1989) · PubMed · Cited by 3,139
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Self-citationSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
CORONARY DISEASE AMONG UNITED STATES SOLDIERS KILLED IN ACTION IN KOREA
Enos, W. F. (1953) · JAMA · doi:10.1001/jama.1953.03690120006002 · Cited by 891
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,025
Lipari, M. T., Li, W., Moran, P., Kong-Beltran, M., Sai, T., Lai, J., Lin, S. J., Kolumam, G. A., Zavala‐Solorio, J., Izrael-Tomasevic, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.380618 · Cited by 95
Acute Kidney Injury During Therapy With an Antisense Oligonucleotide Directed Against PCSK9
van Poelgeest, E. P., Swart, R. M., Betjes, M. G. H., Moerland, M., Weening, J. J., Tessier, Y., Hodges, M. R., Levin, A. A., & Burggraaf, J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.02.359 · Cited by 95
Frikke-Schmidt, R. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.06.005 · Cited by 94
Brænne, I., Kleinecke, M., Reiz, B., Graf, E., Strom, T. M., Wieland, T., Fischer, M., Kessler, T., Hengstenberg, C., Meitinger, T., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.100 · Cited by 94
Diogo, D., Kurreeman, F. A. S., Stahl, E. A., Liao, K. P., Gupta, N., Greenberg, J. D., Rivas, M. A., Hickey, B., Flannick, J. A., Thomson, B. P., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.11.012 · Cited by 95
Duan, Y., Chen, Y., Hu, W., Li, X., Yang, X., Zhou, X., Yin, Z., Kong, D., Yao, Z., Hajjar, D. P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.350181 · Cited by 95
Vergeer, M., Boekholdt, S. M., Sandhu, M. S., Ricketts, S. L., Wareham, N. J., Brown, M. J., Fairé, U. D., Leander, K., Gigante, B., Kavousi, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.912519 · Cited by 94
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
Sun, H. L., Krauss, R. M., Chang, J. T., & Teng, B. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m078360 · Cited by 94
Repurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
O’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
Karagiannis, A. D., Liu, M., Toth, P. P., Zhao, S., Agrawal, D. K., Libby, P., & Chatzizisis, Y. S. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0718-x · Cited by 93
Huang, C., Fornage, M., Lloyd‐Jones, D. M., Wei, G. S., Boerwinkle, E., & Liu, K. (2009) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.108.828467 · Cited by 93
Self-citationEvidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Revitalizing Psychiatric Therapeutics
Hyman, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.181 · Cited by 92
Li, S., Zhang, Y., Xu, R., Guo, Y., Zhu, C., Wu, N., Qing, P., Liu, G., Dong, Q., & Li, J. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1042908 · Cited by 92
FXR an emerging therapeutic target for the treatment of atherosclerosis
Mencarelli, A., & Fiorucci, S. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00997.x · Cited by 92
Costet, P., Hoffmann, M. M., Cariou, B., Guyomarch, B., Konrad, T., & Winkler, K. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.027 · Cited by 92
Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis
Ding, Z., Liu, S., Wang, X., Mathur, P., Dai, Y., Theus, S. A., Deng, X., Fan, Y., & Mehta, J. L. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6631 · Cited by 92
Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis
Perrot, N., Valerio, V., Moschetta, D., Boekholdt, S. M., Dina, C., Chen, H. Y., Abner, E., Martinsson, A., Manikpurage, H. D., Rigade, S., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.05.004 · Cited by 91
Genome editing in cardiovascular diseases
Strong, A., & Musunuru, K. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.139 · Cited by 91
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
Seidah, N. G., Prat, A., Pirillo, A., Catapano, A. L., & Norata, G. D. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz003 · Cited by 91
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Katzmann, J. L., Gouni‐Berthold, I., & Laufs, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.595819 · Cited by 91
Clinical implications of inflammation for cardiovascular primary prevention
Libby, P., & Crea, F. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq022 · Cited by 91
The Genetic Basis of Peripheral Arterial Disease
Kullo, I. J., & Leeper, N. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.303518 · Cited by 91
PCSK9 as a Positive Modulator of Platelet Activation
Camera, M., Rossetti, L., Barbieri, S. S., Zanotti, I., Canciani, B., Trabattoni, D., Ruscica, M., Tremoli, E., & Ferri, N. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.069 · Cited by 91
Emdin, C. A., Khera, A. V., Chaffin, M. D., Klarin, D. M., Natarajan, P., Aragam, K. G., Haas, M. E., Bick, A. G., Zekavat, S. M., Nomura, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03911-8 · Cited by 90
Tyler, J., Choi, S. W., & Tewari, M. (2020) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2020.07.001 · Cited by 90
Zhao, H., Rasheed, H., Nøst, T. H., Cho, Y., Liu, Y., Bhatta, L., Bhattacharya, A., Initiative, G. B. M.-A., Hemani, G., Smith, G. D., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100195 · Cited by 90
Using human genetics to improve safety assessment of therapeutics
Carss, K., Deaton, A. M., Río-Espínola, A. D., Diogo, D., Fielden, M. R., Kulkarni, D. A., Moggs, J. G., Newham, P., Nelson, M. R., Sistare, F. D., et al. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00561-w · Cited by 90
PCSK9 and LDL cholesterol: unravelling the target to design the bullet
Costet, P., Krempf, M., & Cariou, B. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.06.005 · Cited by 90
Vaccine against arteriosclerosis: an update
Chyu, K., Dimayuga, P. C., & Shah, P. K. (2017) · Therapeutic Advances in Vaccines · doi:10.1177/2051013617693753 · Cited by 90
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9
Stein, E. A., & Raal, F. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-022613-090402 · Cited by 89
Garg, A., & Simha, V. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0275 · Cited by 89
Mayer, G., & Poirier, S. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s36984 · Cited by 89
Hooper, A. J., Burnett, J. R., & Watts, G. F. (2014) · Circulation Research · doi:10.1161/circresaha.116.304637 · Cited by 89
Bis, J. C., Heckbert, S. R., Smith, N. L., Reiner, A. P., Rice, K. M., Lumley, T., Hindorff, L. A., Marciante, K. D., Enquobahrie, D. A., Monks, S. A., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.031 · Cited by 89
Alvi, S. S., Ansari, I. A., Khan, I., Iqbal, J., & Khan, M. S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.012 · Cited by 89
Baum, S. J., Toth, P. P., Underberg, J. A., Jellinger, P., Ross, J., & Wilemon, K. (2017) · Clinical Cardiology · doi:10.1002/clc.22713 · Cited by 88
Pirillo, A., Garlaschelli, K., Arca, M., Averna, M. R., Bertolini, S., Calandra, S., Tarugi, P., Catapano, A. L., Arca, M., Averna, M. R., et al. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.07.002 · Cited by 88
Rong, S., Li, B., Chen, L., Sun, Y., Du, Y., Liu, B., Robinson, J. G., & Bao, W. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023690 · Cited by 88
PCSK9 and Atherosclerosis - Lipids and Beyond
Shapiro, M. D., & Fazio, S. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17003 · Cited by 88
Curing atherosclerosis should be the next major cardiovascular prevention goal
Robinson, J. G., & Gidding, S. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.009 · Cited by 87
PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
Hilvo, M., Simolin, H., Metso, J., Ruuth, M., Öörni, K., Jauhiainen, M., Laaksonen, R., & Baruch, A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.004 · Cited by 87
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes
Hess, C. N., Wang, C. C. L., & Hiatt, W. R. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042716-091351 · Cited by 87
Calandra, S., Tarugi, P., Speedy, H. E., Dean, A. F., Bertolini, S., & Shoulders, C. C. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r017855 · Cited by 87
Kent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86
Tavori, H., Rashid, S., & Fazio, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.017 · Cited by 86
Nomura, A., Won, H., Khera, A. V., Takeuchi, F., Ito, K., McCarthy, S., Emdin, C. A., Klarin, D. M., Natarajan, P., Zekavat, S. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311145 · Cited by 86
Human Genetics of Obesity and Type 2 Diabetes Mellitus
Ingelsson, E., & McCarthy, M. I. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002090 · Cited by 86
Mabuchi, H., Nohara, A., Noguchi, T., Kobayashi, J., Kawashiri, M., Inoue, T., Mori, M., Tada, H., Nakanishi, C., Yagi, K., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.005 · Cited by 87
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
Mital, S. R., Musunuru, K., Garg, V., Russell, M. W. W., Lanfear, D. E., Gupta, R. M., Hickey, K. T., Ackerman, M. J., Perez, M. V., Roden, D. M., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/hcg.0000000000000031 · Cited by 86
Experimental and clinical pharmacology: PCSK9 inhibitors - mechanisms of action
Page, M. M., & Watts, G. F. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.060 · Cited by 86
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 86
Andreadou, I., Iliodromitis, E. K., Lazou, A., Görbe, A., Giricz, Z., Schulz, R., & Ferdinandy, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13704 · Cited by 86
Genetics of Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141637 · Cited by 85
From genetic associations to genes: methods, applications, and challenges
Qi, T., Song, L., Guo, Y., Chen, C., & Yang, J. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.04.008 · Cited by 85
Unravelling the functional significance of PCSK9
Lambert, G. C. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3281338531 · Cited by 85
Role of PCSK9 beyond liver involvement
Cariou, B., Si‐Tayeb, K., & May, C. L. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000180 · Cited by 85
Pletcher, M. J., Vittinghoff, E., Thanataveerat, A., Bibbins-Domingo, K. B., & Moran, A. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154288 · Cited by 85
PCSK9 inhibition in the management of familial hypercholesterolemia
Ogura, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.002 · Cited by 84
Homer, V. M., Marais, A. D., Charlton, F., Laurie, A. D., Hurndell, N., Scott, R., Mangili, F., Sullivan, D. R., Barter, P. J., Rye, K.-A., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.022 · Cited by 84
Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management
Najam, O., & Ray, K. K. (2015) · Cardiology and Therapy · doi:10.1007/s40119-015-0037-z · Cited by 84
Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
Stein, E. A., & Swergold, G. D. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0310-3 · Cited by 84
Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder
Lohoff, F. W., Sorcher, J. L., Rosen, A. D., Mauro, K. L., Fanelli, R. R., Momenan, R., Hodgkinson, C. A., Vendruscolo, L. F., Koob, G. F., Schwandt, M. L., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.168 · Cited by 84
Zhang, H., De, T., Zhong, Y., & Perera, M. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1491 · Cited by 84
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
Niederseer, D., Wernly, B., Aigner, E. S., Stickel, F., & Datz, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030467 · Cited by 87
Zhu, Y. M., Anderson, T. J., Sikdar, K. C., Fung, M., McQueen, M., Lonn, E., & Verma, S. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306172 · Cited by 83
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 83
Davignon, J., Dubuc, G., & Seidah, N. G. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0123-6 · Cited by 83
Ason, B. L., van der Hoorn, J. W. A., Chan, J. C. Y., Lee, E. W., Pieterman, E. J., Nguyen, K., Di, M., Shetterly, S., Tang, J. T., Yeh, W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m053207 · Cited by 83
Genetics of coronary artery calcification among African Americans, a meta-analysis
Wojczynski, M. K., Li, M., Bielak, L. F., Kerr, K. F., Reiner, A. P., Wong, N. D., Yanek, L. R., Qu, L., White, C. C., Lange, L. A., et al. (2013) · BMC Medical Genetics · doi:10.1186/1471-2350-14-75 · Cited by 83
Self-citationPlasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study
Jin, K., Park, B. S., Kim, Y.-W., & Vaziri, N. D. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.042 · Cited by 83
A Versatile Nonviral Delivery System for Multiplex Gene‐Editing in the Liver
Gong, J., Wang, H., Lao, Y., Hu, H., Vatan, N. M., Guo, J., Ho, T., Huang, D., Li, M., Shao, D., et al. (2020) · Advanced Materials · doi:10.1002/adma.202003537 · Cited by 82
Towards equitable and trustworthy genomics research
Atutornu, J., Milne, R., Costa, A., Patch, C., & Middleton, A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103879 · Cited by 82
Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis
Lorey, M. B., Öörni, K., & Kovanen, P. T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.841545 · Cited by 82
Genetic insights into therapeutic targets for aortic aneurysms: A Mendelian randomization study
Chen, Y., Xu, X. P., Wang, L., Li, K., Sun, Y., Xiao, L., Dai, J., Huang, M., Wang, Y., & Wang, D. W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104199 · Cited by 82
Plasma PCSK9 levels correlate with cholesterol in men but not in women.
Mayne, J., Raymond, A., Chaplin, A., Cousins, M., Kaefer, N., Gyamera-Acheampong, C., Seidah, N. G., Mbikay, M., Chrétien, M., & Ooi, T. C. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.029 · Cited by 81
Underberg, J. A., Toth, P. P., & Rodríguez, F. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2117498 · Cited by 81
The Evolution and Refinement of Traditional Risk Factors for Cardiovascular Disease
deGoma, E. M., Knowles, J. W., Angeli, F., Budoff, M. J., & Rader, D. J. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e318239b924 · Cited by 81
Usefulness of Mendelian Randomization in Observational Epidemiology
Bochud, M., & Rousson, V. (2010) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph7030711 · Cited by 81
Yu, J., Shah, B. M., Ip, E. J., & Chan, J. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.2.102 · Cited by 81
Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?
Brouwers, M. C. G. J., Jacobs, C., Bast, A., Stehouwer, C. D. A., & Schaper, N. C. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.08.004 · Cited by 80
Du, F., Hui, Y. Y., Zhang, M., Linton, M. F., Fazio, S., & Fan, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.273474 · Cited by 80
PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
Baragetti, A., Balzarotti, G., Grigore, L., Pellegatta, F., Guerrini, U., Pisano, G., Fracanzani, A. L., Fargion, S. R., Norata, G. D., & Catapano, A. L. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317724342 · Cited by 80
PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
Lee, J. S., Mukhopadhyay, P., Mátyás, C., Trojnár, E., Pálóczi, J., Yang, Y. R., Blank, B. A., Savage, C. H., Sorokin, A. V., Mehta, N. N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53603-6 · Cited by 79
What lies ahead for the proprotein convertases?
Seidah, N. G. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05883.x · Cited by 78
Genetics of Lipid and Lipoprotein Disorders and Traits
Dron, J. S., & Hegele, R. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0097-y · Cited by 78
Macchi, C., Banach, M., Corsini, A., Sirtori, C., Ferri, N., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319831500 · Cited by 78
Health equality, race and pharmacogenomics
Magavern, E. F., Gurdasani, D., Ng, F. L., & Lee, S. S. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14983 · Cited by 78
Noguchi, T., Katsuda, S., Kawashiri, M., Tada, H., Nohara, A., Inazu, A., Yamagishi, M., Kobayashi, J., & Mabuchi, H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.018 · Cited by 78
Abboud, S., Karhunen, P. J., Lütjohann, D., Goebeler, S., Luoto, T., Friedrichs, S., Lehtimaki, T., Pandolfo, M., & Laaksonen, R. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001043 · Cited by 77
Li, C., Lin, L., Zhang, W., Zhou, L., Wang, H., Luo, X., Luo, H., Cai, Y., & Zeng, C. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001937 · Cited by 77
PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia
Saavedra, Y. G. L., Dufour, R., Davignon, J., & Baass, A. W. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304406 · Cited by 78
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
Hopewell, J. C., Malik, R., Valdés‐Márquez, E., Worrall, B. B., & Collins, R. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx373 · Cited by 77
Brazel, D. M., Jiang, Y., Hughey, J. M., Turcot, V., Zhan, X., Gong, J., Batini, C., Weissenkampen, J. D., Liu, M., Barnes, D. R., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.11.024 · Cited by 77
Dewpura, T., Raymond, A., Hamelin, J., Seidah, N. G., Mbikay, M., Chrétien, M., & Mayne, J. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06495.x · Cited by 77
Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum
Rahalkar, A. R., & Hegele, R. A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.10.007 · Cited by 77
Nongpiur, M. E., Khor, C. C., Jia, H., Cornes, B. K., Chen, L.-J., Qiao, C., Nair, K. S., Cheng, C., Xu, L., George, R. J., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004089 · Cited by 77
Metadata
- Authors
- Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- The University of Texas Health Science Center at Houston (US)
- Howard Hughes Medical Institute (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1264-1272
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2067539811
- Semantic Scholar
- 5cb1ad66116f87a0743739413b3b5f7f633657f8
- Cited by
- 3,181
- References
- 27
- Citations by year
- 2026: 130 · 2025: 121 · 2024: 150 · 2023: 182 · 2022: 169 · 2021: 175 · 2020: 193 · 2019: 180 · 2018: 210 · 2017: 229 · 2016: 235 · 2015: 244 · 2014: 171 · 2013: 145 · 2012: 126
- FWCI
- 104.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- W. M. Keck Foundation
- Donald W. Reynolds Foundation
- National Institutes of Health (n01hc55021-47-0-1, n01hc55020-39-0-0, n01hc55016-37-0-0, n01hc055022-024, n01hc55019-35-0-1, n01hc55018-38-0-1, N01-HC55020, N01-HC-55021, HL20948, N01-HC-55019, N01-HC-55022, N01-HC55016, N01-HC55018, N01-HC-55015, n01hc55015-48-0-1)
- National Heart, Lung, and Blood Institute (N01-HC55022, N01-HC-55018, HL-20948, N01 HC 55020, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022, N01 HC 55019, N01-HC55016, P01HL020948, N01‐HC‐55015, N01-HC55021)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9, LDL cholesterol, coronary artery disease, myocardial infarction, coronary revascularization, nonsense mutation, genetic variants, LDL cholesterol lowering, cardiovascular risk, Atherosclerosis Risk in Communities Study, black and white populations
- MeSH terms
- Proprotein Convertase 9, Black or African American, Carotid Arteries, Coronary Disease, Female, Gene Frequency, Genotype, Humans, Hypolipoproteinemias, Cholesterol, LDL, Male, Middle Aged, Risk, Serine Endopeptidases, United States, Genetic Variation, Cohort Studies, Incidence, Proportional Hazards Models, Codon, Nonsense, Proprotein Convertases, Black People, White People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
